Kenalog Dosing for Trigger Point Injection
For trigger point injections in adults, use 10-20 mg of Kenalog (triamcinolone acetonide) per trigger point, with the FDA label indicating that doses up to 10 mg for smaller areas and up to 40 mg for larger areas have usually been sufficient. 1
Recommended Dosing Approach
The FDA-approved Kenalog label provides clear guidance for local injection therapy 1:
- Smaller areas: Up to 10 mg per injection site
- Larger areas: Up to 40 mg per injection site
- Multiple sites: Total cumulative dose up to 80 mg when injecting several areas in one session
Practical Application for Trigger Points
For typical trigger point injections, I recommend starting with 10-20 mg per trigger point. This range balances efficacy with safety:
- 10 mg is appropriate for most standard trigger points in areas like the trapezius, levator scapulae, or paraspinal muscles
- 20 mg may be used for larger muscle groups or particularly resistant trigger points
- Avoid exceeding 40 mg in any single injection site
- Keep total session dose under 80 mg when treating multiple trigger points
Technical Considerations
The FDA label emphasizes critical injection technique 1:
- Inject into the area of greatest tenderness (the trigger point itself)
- Avoid subcutaneous injection - atrophy of subcutaneous fat may occur if not properly placed into the muscle
- Use strict aseptic technique
- Shake the vial before use to ensure uniform suspension
- Inject without delay after drawing up to prevent settling in the syringe
Important Caveats
Tissue atrophy risk: The FDA label specifically warns that care must be taken to avoid injecting the suspension into tissues surrounding the site, particularly in the deltoid region, as this may lead to tissue atrophy 1. This is especially relevant for trigger point injections where precise placement is critical.
Not for tendon substance: If treating areas near tendons (like epicondylitis), infiltrate into the area of tenderness but ensure injection is made into the tendon sheath rather than the tendon substance itself 1.
The evidence from trigger finger studies 2, 3 demonstrates a dose-response relationship with triamcinolone, where 20 mg showed superior outcomes compared to lower doses, supporting the use of adequate dosing for musculoskeletal conditions.